Article Text

Download PDFPDF
Review
Advances in the management of glioblastoma
  1. Ruichong Ma1,2,3,
  2. Martin J B Taphoorn4,5,
  3. Puneet Plaha1,3,6
  1. 1 Department of Neurosurgery, Oxford University Hospitals NHS Foundation Trust, Oxford, Oxfordshire, UK
  2. 2 Human Immunology Unit, Radcliffe Department of Medicine, University of Oxford, Oxford, UK
  3. 3 Nuffield Department of Surgery, University of Oxford, Oxford, UK
  4. 4 Neurology, Leiden University Medical Center, Leiden, The Netherlands
  5. 5 Neurology, Medical Center Haaglanden, The Hague, The Netherlands
  6. 6 Nuffield Department of Clinical Neurosciences, University of Oxford, Oxford, UK
  1. Correspondence to Puneet Plaha, Department of Neurosurgery, Oxford University Hospitals NHS Foundation Trust, Oxford OX3 9DU, Oxfordshire, UK; puneet.plaha{at}ouh.nhs.uk

Abstract

Glioblastoma (GB) is the most common and most malignant primary brain tumour in adults. Despite much effort, gold standard therapy has not changed since the introduction of adjuvant temozolomide in 2005 and prognosis remains poor. Despite this, there has been significant improvement in the surgical technology and technique, that has allowed for increased rates of safe maximal resection of the tumour. In addition, our increased knowledge of the biology of GB has revealed more potential targets, especially in the field of immunotherapy, which has been successful in revolutionising treatment of other cancers. We review the current best practice for the treatment of GB and explore some of the more recent advances in GB management from both a surgical and molecular therapeutic perspective.

  • neurooncology
  • immunology
  • neurosurgery
  • neuroradiology
  • tumours

Statistics from Altmetric.com

Footnotes

  • Contributors RM and PP were commissioned the article. RM wrote the article. PP and MJBT reviewed and edited the manuscript.

  • Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

  • Competing interests None declared.

  • Provenance and peer review Commissioned; externally peer reviewed.

  • Supplemental material This content has been supplied by the author(s). It has not been vetted by BMJ Publishing Group Limited (BMJ) and may not have been peer-reviewed. Any opinions or recommendations discussed are solely those of the author(s) and are not endorsed by BMJ. BMJ disclaims all liability and responsibility arising from any reliance placed on the content. Where the content includes any translated material, BMJ does not warrant the accuracy and reliability of the translations (including but not limited to local regulations, clinical guidelines, terminology, drug names and drug dosages), and is not responsible for any error and/or omissions arising from translation and adaptation or otherwise.

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.